- Home
- PSHG vs GTBP Comparison
PSHG vs GTBP Comparison
Compare PSHG & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSHG | GTBP |
|---|---|---|
| Founded | 2010 | 1965 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.9M | 17.7M |
| IPO Year | 2010 | 2016 |
Fundamental Metrics
Financial Performance| Metric | PSHG | GTBP |
|---|---|---|
| Price | $1.67 | $0.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 47.4K | ★ 1.3M |
| Earning Date | 05-26-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $49.57 | N/A |
| Revenue Next Year | $2.73 | N/A |
| P/E Ratio | $1.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.61 | $0.26 |
| 52 Week High | $2.58 | $2.29 |
Technical Indicators
Market Signals| Indicator | PSHG | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 51.00 | 38.19 |
| Support Level | $1.71 | $0.29 |
| Resistance Level | $1.99 | $0.46 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 91.30 | 9.83 |
Price Performance
Historical ComparisonAbout PSHG Performance Shipping Inc.
Performance Shipping Inc is a shipping company. The company is a provider of shipping transportation services through the ownership of tanker vessels. The company's vessels are employed on time charters with liner companies carrying container vessels and cargo along various shipping routes. It owns and operates Aframax and Suezmax tanker vessels.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.